Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "Global Neutropenia Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Neutropenia Market estimated at USD 4.34 Bn in 2023, is expected to reach USD 5.86 Bn by 2028 growing at a CAGR of 6.21%.
Neutropenia is a medical disorder characterized by an unusually low quantity of neutrophils, a type of white blood cell that plays an important part in the immunological response of the body. It can weaken the immune system, making people more vulnerable to infections, and it can be caused by a variety of factors, including particular drugs or medical conditions.
The rising prevalence of leukemia, a kind of blood cancer frequently associated with neutropenia, is a major market driver for neutropenia. As the number of leukemia patients increases, so does the demand for treatments that target low neutrophil numbers. This tendency has generated an emphasis on developing medicines that increase neutrophil production, hence improving patient outcomes and quality of life.
Increased research and development initiatives have resulted from a better understanding of neutropenia's influence on patients. To fight neutropenia more effectively, pharmaceutical companies are investing in new drug research and treatment options. The launch of new medications with enhanced efficacy and safety profiles improves the market outlook overall.
The market for cancer supportive treatments, especially those for neutropenia management, has seen a trend away from more expensive branded medications and towards less priced biosimilars. This transformation is being driven by cost-effectiveness and increasing access to high-quality treatment choices, which will broaden the reach of the neutropenia market and benefit patients worldwide.
The emergence of a strong pharmacological pipeline primarily addressing neutropenia treatment creates a market potential. With multiple promising medications in various phases of research, this signifies a substantial advancement in neutropenia management. When these pharmaceuticals hit the market, they will be able to address unmet medical needs, attract investment, and enhance patient outcomes.
However, the market for neutropenia is restricted by high treatment costs. The costs of treating neutropenia, including drugs and supportive care, can be prohibitively expensive for individuals and healthcare systems, limiting access and uptake of these therapies.
The neutropenia market faces the challenge of managing tight laws and regulations for product approvals. Long and complicated approval processes imposed by regulatory bodies can cause delays in drug development and market access, providing challenges for pharmaceutical companies wanting to deliver new neutropenia therapies.
Market Segmentation:
- The Global Neutropenia Market is segmented based on Treatment, Distribution Channel, and Geography.
- By Treatment, the Global Neutropenia Market is classified into Colony-Stimulating Factors (CSFs), Antibiotics, and Antivirals.
- Colony-Stimulating Factors (CSFs) hold a larger market share. CSFs are especially designed to increase white blood cell production, so addressing the underlying cause of neutropenia, making them a primary and more targeted therapy option for treating this illness.
- By Distribution Channel, the Global Neutropenia Market is classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- Hospital Pharmacies hold a significant market share. Due to the specialized nature of these treatments and the necessity for close monitoring, healthcare facilities play an important role in dispensing and managing neutropenia drugs.
- By Geography, the Global Neutropenia Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
- The Americas hold a larger market share. This was due to parameters such as the region's increased prevalence of neutropenia-related illnesses, improved healthcare infrastructure, and greater availability to advanced medical treatments.
Company Profiles
The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are BeyondSpring Pharmaceuticals, Coherus Biosciences, Myelo Therapeutics, Spectrum Pharmaceuticals, etc
Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Report Highlights:
- A complete analysis of the market, including the parent industry
- Important market dynamics and trends
- Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
- Market segmentation
- Competitive Analysis: Comparative analysis of competitor
- Historical, current, and projected size of the market based on value and volume
- Market size of the US states
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 199 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $4.34 Billion |
| Forecasted Market Value (USD) by 2028 | $5.86 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Company Coverage:
- Amgen
- Baxter International Inc.
- BeyondSpring Pharmaceuticals
- Biogen Inc.
- Cantargia
- Coherus Biosciences
- Dong-A ST
- Enzychem Lifesciences
- Gilead Sciences, Inc.
- Kyowa Kirin
- Merck & Co., Inc.
- Myelo Therapeutics
- Mylan Institutional (Fulphila)
- Novartis Pharmaceuticals
- Partner Therapeutics
- Pfizer
- Sandoz (Novartis)
- Sanofi S.A.
- Spectrum Pharmaceuticals
- Teva Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/r/73zwrd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
